ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Industrials / NIKI
UCAR (19) RETO (21) XPON (33) DFLI (25) ⌘ Pro Terminal →

Niki BioSolutions Inc. (NIKI) — RQD Stock Rating Cockpit

$1.69 -4.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.67

Niki BioSolutions Inc. (NIKI) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NIKI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.69 (-4.52% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 486 tracked Industrials issuers, NIKI ranks #393 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NIKI compare to UCAR and RETO in the Industrials sector?
▼

Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.3M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NIKI?
▼

Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $7.9M in revenue (+15.9% YoY), -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.67 (-1.00%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (4)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.8% Base Target
$18 Bull$1 Base$1 Bear
📬 FREE NIKI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NIKI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY NIKI SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (31% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 25 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$2.63-22.8% Next Q
Q2 (-2Q)
37
Grade E$2.03-5.4% Next Q
Q3 (-1Q)
35
Grade E$1.92-12% Next Q
Current
32
Grade E$1.69-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NIKI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NIKI currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Industrials with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.37) and Max Pain ($1.77) forces dealer call-delta covering toward $18.06.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NIKI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NIKI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
2530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$1.69H: $17
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on NIKI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-5.9% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

8/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like NIKI
  • ✓Established market leader in Industrials with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NIKI)

  • ✓Walkthrough of NIKI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NIKI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -79.88%▼ SUPPORT BREAKDOWN
2026-11-03O $1.96H $1.96L $1.69C $1.69VOL 10.0K
RES: $6.59SUP: $2.39SMA50: $4.37SMA200: $7.63
$14.75$11.21$7.67$4.13$0.59RES $6.59SUP $2.39$1.692026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NIKI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NIKI Butterfly Map → + Track NIKI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +15.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NIKI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NIKI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NIKI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NIKI)

Industrials Rank #393 of 486 ⚔️ UCAR vs NIKI Full Matrix →

1. Head-to-Head Industrials Peer Comparison (NIKI vs. UCAR, RETO, XPON, DFLI)

Industry: Industrial Machinery/Components (208 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, Niki BioSolutions Inc. (NIKI) ranks #393 by composite RQD confidence (32/100, grade E) and #461 by equity capitalization ($5.2M). Within this direct 5-issuer industry benchmark cohort, NIKI leads on earnings valuation at N/A trailing P/E, while NIKI leads on capital efficiency and profitability with -5.9% ROIC and — gross margin. XPON currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with NIKI at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NIKI ACTIVE
Niki BioSolutions Inc.
E 32/100 — — -5.9% -4.52% $5.2M Benchmark Subject
UCAR
U Power Limited (Class A)
E 19/100 — 36.3% -18.5% +4.69% $5.3M /ucar-vs-niki →
RETO
ReTo Eco-Solutions Inc. (Class A)
E 21/100 — 35.3% -35.0% -6.59% $4.2M /reto-vs-niki →
XPON
Expion Energy Inc.
E 33/100 — 13.9% -35.0% +1.96% $3.6M /xpon-vs-niki →
DFLI
Dragonfly Energy Holdings Corp. (NV)
E 25/100 — 26.7% -35.0% -4.21% $3.6M /dfli-vs-niki →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001734005 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported GAAP revenue of $7.9M (+15.9% vs. FY2024 revenue of $6.8M , and +1719.8% cumulative change since FY2023) , GAAP net income of -$1.4M, operating cash flow of -$1.8M, and free cash flow of -$1.8M (-54.4% YoY). On the balance sheet, NIKI closed FY2025 with $18.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.9M -$1.4M -$1.8M -$1.8M $18.7M —
FY2024 (FY) 2024-12-31 $6.8M -$4.3M -$1.2M -$1.2M $16.1M —
FY2023 (FY) 2023-12-31 $431.4K -$2.8M -$7.7M -$7.7M — —

3. NIKI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NIKI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Niki BioSolutions Inc. (NASDAQ: NIKI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.69 (-4.52% 1D, market cap $5.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 486 tracked Industrials issuers, NIKI ranks #393 in composite RQD confidence.

How does NIKI compare to UCAR and RETO in the Industrials sector?

Within the Industrials sector (Industrial Machinery/Components), NIKI carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -5.9%. By comparison, UCAR (U Power Limited (Class A)) holds a E grade (19/100 RQD, P/E N/A, ROIC -18.5%, cap $5.3M) and RETO (ReTo Eco-Solutions Inc. (Class A)) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $4.2M). Among the 5-stock peer group, NIKI leads on earnings multiple (N/A) while NIKI leads on capital efficiency (-5.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NIKI?

Per NIKI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001734005), Niki BioSolutions Inc. generated $7.9M in revenue (+15.9% YoY), -$1.4M in net income, and -$1.8M in free cash flow against $18.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Industrials with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NIKI trading relative to its 50-day, 200-day, and 52-week technical levels?

NIKI last traded at $1.69 (-4.52% on volume of 25,520 shares), positioning the stock -61.33% below its 50-day simple moving average ($4.37) and -77.85% below its 200-day simple moving average ($7.63). Across its 52-week range of $1.70 to $17.20, NIKI sits at the 0.0% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.48 to $1.90).

Direct Sub-Reports: NIKI RQD Cockpit NIKI 12M Forecast NIKI Earnings & Move NIKI Dividends & DRIP NIKI Insiders & 13F NIKI Whale Options NIKI Profit Sankey NIKI News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

NIKI — Niki BioSolutions Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Niki BioSolutions Inc. (NIKI) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.69 (-4.52% 1D, market capitalization $5.2M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -5.9%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Niki BioSolutions Inc. Is a NASDAQ-listed issuer classified in the Industrials sector, Industrial Machinery/Components industry. Per the recent news wire, the company has announced a supply agreement for APOE genotyping with Charter Research, indicating a genetic testing product offering.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Niki BioSolutions Inc. (NIKI) reported $7.9M in annual revenue (up from $6.8M in FY2024, +15.9% YoY) and -$1.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($431.4K revenue, -$2.8M net income) through FY2025, NIKI scaled operating cash flow to -$1.8M and free cash flow to -$1.8M, backed by $18.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Industrials with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.70 – $17.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation analysis are — The only observable cross-reference is that the sector classification (Industrials) does not align with the genetic-testing activity described in the news wire, which a prospective investor should keep in mind when assessing the business and its comparables.

  • Key Question #1: Can NIKI sustain or expand its — operating margin and -5.9% ROIC against Industrial Machinery/Components peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.9M and free cash flow of -$1.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NIKI's equity valuation to Industrials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NIKI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Niki BioSolutions Inc. (NIKI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NIKI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NIKI Bull vs. Bear Conversation Board — What's Your Call at $1.69?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NIKI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NIKI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $2.11 (+19.2%)
📌 Pinned Debate

Recent news flow includes a commercial supply agreement for APOE genotyping with Charter Research and $3.5M of reported FY 2025 cash, w

Don't sleep on NIKI's setup in Industrials. Recent news flow includes a commercial supply agreement for APOE genotyping with Charter Research and $3.5M of reported FY 2025 cash, which provides some runway for the company's operations.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (32/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@ShortSeller_Dan Shorting a 3/20 institutional whale-flow stock at $1.77 is dangerous when funds are rotating into Industrials.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.47 (-16.9%)
Spot @ $1.77

Reported net losses in every period, negative free cash flow, 0% margins, ROIC of -5.9%, and a Piotroski F-Score of 1/9 point to weak f

Fading this rally in NIKI at $1.77. Reported net losses in every period, negative free cash flow, 0% margins, ROIC of -5.9%, and a Piotroski F-Score of 1/9 point to weak fundamentals while a new ATM equity program raises dilution risk.. With a beta of 1.0 and the stock sitting at $1.77 (52-wk range $1.70–$17.20), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%